BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/30/2019 2:14:06 AM | Browse: 1668 | Download: 2782
Publication Name World Journal of Gastroenterology
Manuscript ID 50618
Country China
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article which was selected byan in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Basic Study
Article Title Oncogenic ADAM28 induces gemcitabine resistance and predicts poor prognosis in pancreatic cancer
Manuscript Source Unsolicited Manuscript
All Author List Li Wei, Jing-Yun Wen, Jie Chen, Xiao-Kun Ma, Dong-Hao Wu, Zhan-Hong Chen and Jiang-Long Huang
ORCID
Author(s) ORCID Number
Li Wei http://orcid.org/0000-0003-2999-0979
Jing-Yun Wen http://orcid.org/0000-0001-5560-7115
Jie Chen http://orcid.org/0000-0002-7503-8236
Xiao-Kun Ma http://orcid.org/0000-0002-6793-0232
Dong-Hao Wu http://orcid.org/0000-0002-8340-2253
Zhan-Hong Chen http://orcid.org/0000-0003-3192-9026
Jiang-Long Huang http://orcid.org/0000-0002-3784-8465
Funding Agency and Grant Number
Corresponding Author Jiang-Long Huang, MD, Associate Professor, Chief Doctor, Department of Gastrointestinal Surgery, The Third Affiliated Hospital of Sun Yat-sen University, No.600 Tianhe Rd, Guangzhou 510630, Guangdong Province, China. leichende21743@163.com
Key Words ADAM28; Drug resistance; Overexpression; Poor prognosis; Drug metabolism; Gemcitabine
Core Tip This study demonstrated that ADAM28 was overexpressed in pancreatic cancer, and the ADAM28 level was elevated in the gemcitabine-resistant pancreatic cancer cells. Furthermore, ADAM28 overexpression could predict the poor prognosis in pancreatic cancer. Also, overexpression of ADAM28 could attenuate the cell viability inhibition by gemcitabine. Similarly, knockdown of ADAM28 could enhance the cell viability inhibition by gemcitabine. Interestingly, ADAM28 was identified as a mediator, which was closely involved in the regulation of the drug resistance signaling pathway. ADAM28 was identified as a novel therapeutic target for pancreatic cancer, especially in the drug resistance of gemcitabine.
Publish Date 2019-09-30 02:14
Citation Wei L, Wen JY, Chen J, Ma XK, Wu DH, Chen ZH, Huang JL. Oncogenic ADAM28 induces gemcitabine resistance and predicts poor prognosis in pancreatic cancer. World J Gastroenterol 2019; 25(37): 5590-5603
URL https://www.wjgnet.com/1007-9327/full/v25/i37/5590.htm
DOI https://dx.doi.org/10.3748/wjg.v25.i37.5590
Full Article (PDF) WJG-25-5590.pdf
Full Article (Word) WJG-25-5590.docx